LGND Nasdaq Biotechnology Financials FY2016βFY2025
Ligand Pharmaceuticals had $268M of revenue in fiscal 2025, up 60.4% on the year before. Over five years, revenue changed +10.4% a year on average.
Hi! I read Ligand Pharmaceuticalsβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+60.4%
Yes. Sales grew 60.4% last year.
Does it make a profit?
46.4%
Yes. It keeps 46.4% of every sale as profit.
Does profit turn into cash?
18.2%
Yes. 18.2% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
32.8x
One share costs 32.8 times its yearly profit per share. Typical for its sector: 27.9x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Ligand Pharmaceuticals had $268M of revenue in fiscal 2025, up 60.4% on the year before.
Over five years, revenue changed +10.4% a year on average.
Its operating margin was 15.3%, up 28.8Β pts: of every 100 in sales, about 15 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Ligand Pharmaceuticals made $125M of net profit in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was $48.9M in fiscal 2025, 18.2% of revenue.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA summarises the numbers
Ligand Pharmaceuticals returned $15.0M to shareholders in fiscal 2025, 31% of free cash flow.
The diluted share count rose 11.0%.
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders sold $34.7M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$34.7M
9 insiders
Of sales under plans
69%
$24.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $304.07 | $1.5M | Form 4 |
| Sep 10, 2026 | Martine ZimmermannDirector | Sold | 1,200 | $285.00 | $0.3M | Form 4 |
| Sep 3, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $286.09 | $1.4M | Form 4 |
| Aug 12, 2026 | Octavio EspinozaChief Financial Officer | Sold plan | 31,641 | $292.07 | $9.2M | Form 4 |
| Aug 12, 2026 | Jason HaasDirector | Sold | 7,138 | $292.81 | $2.1M | Form 4 |
| Aug 3, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $288.99 | $1.4M | Form 4 |
| Jul 1, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $313.28 | $1.6M | Form 4 |
| Jun 16, 2026 | Stephen L SabbaDirector | Sold | 2,145 | $254.00 | $0.5M | Form 4 |
| Jun 12, 2026 | Jason HaasDirector | Sold | 6,461 | $255.58 | $1.7M | Form 4 |
| Jun 11, 2026 | Jason AryehDirector | Sold | 4,500 | $250.00 | $1.1M | Form 4 |
| Jun 10, 2026 | Jason AryehDirector | Sold | 500 | $250.00 | $0.1M | Form 4 |
| Jun 10, 2026 | John L LamattinaDirector | Sold | 4,591 | $250.88 | $1.2M | Form 4 |
| Jun 1, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $227.06 | $1.1M | Form 4 |
| May 13, 2026 | John W KozarichDirector | Sold plan | 1,575 | $223.50 | $0.4M | Form 4 |
| May 12, 2026 | John W KozarichDirector | Sold plan | 459 | $224.00 | $0.1M | Form 4 |
| May 1, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $231.31 | $1.2M | Form 4 |
| May 1, 2026 | John W KozarichDirector | Sold plan | 467 | $231.80 | $0.1M | Form 4 |
| Apr 1, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $201.24 | $1.0M | Form 4 |
| Apr 1, 2026 | John W KozarichDirector | Sold plan | 467 | $202.22 | $0.1M | Form 4 |
| Mar 23, 2026 | Stephen L SabbaDirector | Sold | 1,000 | $207.87 | $0.2M | Form 4 |
| Mar 11, 2026 | Octavio EspinozaChief Financial Officer | Sold plan | 3,057 | $225.00 | $0.7M | Form 4 |
| Mar 6, 2026 | John L LamattinaDirector | Sold | 2,161 | $200.76 | $0.4M | Form 4 |
| Mar 4, 2026 | Octavio EspinozaChief Financial Officer | Sold plan | 13,423 | $205.83 | $2.8M | Form 4 |
| Mar 4, 2026 | Andrew ReardonCLO & Secretary | Sold plan | 5,000 | $206.35 | $1.0M | Form 4 |
| Mar 3, 2026 | Stephen L SabbaDirector | Sold | 2,034 | $201.50 | $0.4M | Form 4 |
| Mar 2, 2026 | John W KozarichDirector | Sold plan | 467 | $200.50 | $0.1M | Form 4 |
| Feb 2, 2026 | John W KozarichDirector | Sold plan | 467 | $195.91 | $0.1M | Form 4 |
| Jan 2, 2026 | John W KozarichDirector | Sold plan | 467 | $189.58 | $0.1M | Form 4 |
| Dec 12, 2025 | Octavio EspinozaChief Financial Officer | Sold | 1,804 | $188.31 | $0.3M | Form 4 |
| Dec 1, 2025 | John W KozarichDirector | Sold plan | 467 | $195.84 | $0.1M | Form 4 |
| Nov 7, 2025 | Nancy Ryan GrayDirector | Sold | 6,571 | $205.45 | $1.4M | Form 4 |
| Nov 7, 2025 | John L LamattinaDirector | Sold | 4,179 | $205.45 | $0.9M | Form 4 |
| Nov 3, 2025 | John W KozarichDirector | Sold plan | 467 | $191.05 | $0.1M | Form 4 |
| Oct 1, 2025 | John W KozarichDirector | Sold plan | 467 | $179.45 | $0.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Ligand Pharmaceuticals can carry it.
KIRA summarises the numbers
Ligand Pharmaceuticals has $287M more cash than debt.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $341M | $212M | $170M | $256M | $734M |
| Debt incl. finance leases | $321M | $76.7M | $0.0M | $0.1M | $446M |
| Net debt / EBITDA | β0.1x | β2.5x | β3.5x | β20.3x | β3.8x |
| Debt / equity | 0.4x | 0.1x | 0.0x | 0.0x | 0.4x |
| Interest coverage | 5.3x | 1.7x | 18.2x | β7.4x | 8.7x |
| Current ratio | 11.2x | 2.7x | 14.2x | 8.9x | 22.2x |
| Quick ratio | 10.5x | 2.5x | 12.7x | 8.6x | 22.0x |
| Total assets | $1.3B | $763M | $787M | $942M | $1.6B |
| Total liabilities | $476M | $165M | $86.3M | $111M | $543M |
| Shareholders' equity | $821M | $598M | $701M | $830M | $1.0B |
| Net debt (β = net cash) | β$20.3M | β$135M | β$170M | β$256M | β$287M |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KIRA summarises the numbers
Its return on capital was 4.9%: every 100 invested in the business earned about 5 in a year.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
Ligand Pharmaceuticals passes 5 of 8 financial health tests (Piotroski F-score).
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 6 / 8 | 3 / 8 | 5 / 8 |
| Accruals ratio | 0.3% | β11.7% | 6.0% |
| Altman Z'' | 12.55 | 11.45 | 6.75 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
What does the share cost, and how does it compare?
What could happen to the share if things go badly, normally or very well? Pick a story or make your own. These are examples, not forecasts or price targets.
KIRA summarises the numbers
At $308.30 a share, the company is worth $6.7B: 32.8 times its earnings of the last four quarters.
Tap one to see how it is built. Swipe for more.
Share in 5 years
$507.40
+10% a year
If you put in $1,000 today: $1,646
At 32x, earnings only need to grow 0.5% a year for the share to be worth todayβs price in 5 years. Faster, you gain; slower, you lose.
These are examples, not forecasts: nobody knows which will happen. Price in 5 years = earnings per share then Γ the P/E then. Dividends are not included.
Value per share
β
Adds net cash of $287M and divides by 20.3M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 32.3x Β· peers 27.1x Β· sector 27.9x.
In plain words: In the long run a share tends to follow two things: how much the company earns per share, and how many times those earnings the market is willing to pay (the P/E). Move those two levers and you see what the share could be worth. Different guesses give very different answers.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
KIRA summarises the numbers
Ligand Pharmaceuticals grew sales faster than 3 of its 4 similar companies.
Its P/E is higher than 1 of 2.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND | $6.7B | 60.4% | 15.3% | 18.2% | 4.9% | 32.8x | 5 | |
| Krystal Biotech KRYS | $9.6B | 33.9% | 41.5% | 48.6% | 43.6% | 39.3x | 5 | Compare β |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.8x | 5 | Compare β |
| Repligen RGEN | β | 16.4% | 7.5% | 12.7% | 2.4% | β | β | Compare β |
| Cytokinetics CYTK | β | 376.6% | β695.4% | β607.5% | β | β | β | Compare β |
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $109M | $141M | $252M | $120M | $164M | $242M | $196M | $131M | $167M | $268M |
| Gross profit | $103M | $136M | $245M | β | β | β | β | β | β | β |
| Research and development | $21.2M | $26.9M | $27.9M | $55.9M | $40.5M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M |
| Operating income | $43.9M | $68.1M | $164M | $807M | $37.5M | $104M | $3.0M | $11.9M | β$22.6M | $41.0M |
| Interest expense | $12.8M | $13.5M | $48.3M | $35.7M | $27.4M | $19.6M | $1.8M | $0.7M | $3.0M | $4.7M |
| Pretax income | $8.0M | $57.2M | $173M | $797M | $1.3M | $72.2M | $36.0M | $63.7M | $2.5M | $159M |
| Income tax | $10.3M | $44.7M | $30.0M | $167M | β$5.3M | β$4.1M | $41.2M | $9.8M | $6.5M | $34.5M |
| Net income | β$1.6M | $12.6M | $143M | $629M | β$3.0M | $57.1M | β$33.4M | $52.2M | β$4.0M | $125M |
| Diluted EPS | β$0.08 | $0.53 | $5.96 | $31.85 | β$0.18 | $3.31 | β$1.98 | $2.94 | β$0.22 | $6.13 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $60.7M | $88.6M | $194M | β$29.3M | $54.6M | $78.8M | $138M | $49.6M | $97.0M | $49.4M |
| Capital expenditure | $1.8M | $2.2M | $0.9M | $2.6M | $4.5M | $8.8M | $17.9M | $3.5M | $1.8M | $0.5M |
| Free cash flow | $58.9M | $86.4M | $193M | β$31.9M | $50.1M | $70.0M | $120M | $46.1M | $95.2M | $48.9M |
| Depreciation and amortization | $11.3M | $11.0M | $12.8M | $18.4M | $25.7M | $51.1M | $51.5M | $36.5M | $35.2M | $33.8M |
| Stock-based compensation | $18.9M | $24.9M | $20.8M | $24.5M | $30.7M | $38.8M | $60.3M | $25.7M | $41.1M | $46.8M |
| Acquisitions | $92.5M | $26.7M | $5.9M | $11.8M | $405M | $0.0M | $0.0M | $10.4M | $0.0M | $0.0M |
| Share buybacks | $3.9M | $2.0M | $123M | $453M | $78.0M | $0.0M | $0.0M | $0.0M | $0.0M | $15.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $3.9M | $2.0M | $123M | $453M | $78.0M | $0.0M | $0.0M | $0.0M | $0.0M | $15.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $141M | $202M | $718M | $1.1B | $411M | $341M | $212M | $170M | $256M | $734M |
| Total debt | β | $225M | $636M | $639M | $442M | $321M | $76.7M | $0.0M | $0.0M | $446M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.1M | $6.7M | $0.1M | $0.0M | $0.0M | $0.1M | $0.0M |
| Current assets | $163M | $237M | $871M | $1.1B | $501M | $465M | $264M | $237M | $332M | $832M |
| Current liabilities | $227M | $239M | $82.2M | $17.0M | $100M | $41.7M | $98.8M | $16.8M | $37.1M | $37.4M |
| Inventory | $1.9M | $4.4M | $7.1M | $7.3M | $26.5M | $27.3M | $13.3M | $24.0M | $14.1M | $9.1M |
| Property and equipment, net | $1.8M | $4.2M | $5.4M | $7.2M | $13.2M | $13.2M | $12.5M | $15.6M | $15.1M | $3.6M |
| Total assets | $602M | $671M | $1.3B | $1.5B | $1.4B | $1.3B | $763M | $787M | $942M | $1.6B |
| Total liabilities | $231M | $252M | $700M | $728M | $653M | $476M | $165M | $86.3M | $111M | $543M |
| Shareholders' equity | $341M | $400M | $561M | $767M | $710M | $821M | $598M | $701M | $830M | $1.0B |
| Margins | ||||||||||
| Gross margin | 94.9% | 96.2% | 97.5% | β | β | β | β | β | β | β |
| Operating margin | 40.3% | 48.3% | 65.1% | 671.0% | 22.9% | 43.0% | 1.6% | 9.1% | β13.5% | 15.3% |
| EBITDA margin | 50.6% | 56.0% | 70.2% | 686.3% | 38.6% | 64.1% | 27.8% | 36.9% | 7.6% | 27.9% |
| Net margin | β1.5% | 8.9% | 57.0% | 523.2% | β1.8% | 23.7% | β17.0% | 39.7% | β2.4% | 46.4% |
| FCF margin | 54.0% | 61.2% | 76.8% | β26.5% | 30.7% | 29.0% | 61.1% | 35.1% | 57.0% | 18.2% |
| Returns | ||||||||||
| Return on capital | β | β | 30.0% | 156.4% | 6.9% | 13.4% | 0.2% | 2.0% | β2.1% | 4.9% |
| Return on capital employed | 13.4% | 16.9% | 20.3% | 60.8% | 2.7% | 8.3% | 0.3% | 1.7% | β2.7% | 3.4% |
| Return on equity | β0.6% | 3.4% | 29.8% | 94.8% | β0.4% | 7.5% | β4.7% | 8.0% | β0.5% | 13.5% |
| Return on assets | β0.3% | 2.0% | 14.8% | 45.7% | β0.2% | 4.3% | β3.2% | 6.7% | β0.5% | 10.0% |
| Growth | ||||||||||
| Revenue growth | 51.5% | 29.5% | 78.2% | β52.2% | 36.0% | 47.7% | β18.8% | β33.1% | 27.3% | 60.4% |
| Net income growth | β100.7% | β | 1,041.5% | 339.1% | β100.5% | β | β158.4% | β | β107.7% | β |
| EPS growth | β100.7% | β | 1,024.5% | 434.4% | β100.6% | β | β159.8% | β | β107.5% | β |
| FCF growth | 41.4% | 46.8% | 123.5% | β116.5% | β | 39.7% | 71.2% | β61.6% | 106.8% | β48.6% |
| Share count change | β1.9% | 12.7% | 2.5% | β17.9% | β14.8% | 2.5% | β2.2% | 5.3% | 3.0% | 11.0% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | 0.3x | β0.5x | β0.5x | 0.6x | β0.1x | β2.5x | β3.5x | β20.3x | β3.8x |
| Debt / equity | β | 0.6x | 1.1x | 0.8x | 0.6x | 0.4x | 0.1x | 0.0x | 0.0x | 0.4x |
| Interest coverage | 3.4x | 5.1x | 3.4x | 22.6x | 1.4x | 5.3x | 1.7x | 18.2x | β7.4x | 8.7x |
| Current ratio | 0.7x | 1.0x | 10.6x | 66.1x | 5.0x | 11.2x | 2.7x | 14.2x | 8.9x | 22.2x |
| Quick ratio | 0.7x | 1.0x | 10.5x | 65.7x | 4.7x | 10.5x | 2.5x | 12.7x | 8.6x | 22.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.7% | 1.5% | 0.4% | 2.1% | 2.7% | 3.6% | 9.1% | 2.7% | 1.1% | 0.2% |
| Stock comp / revenue | 17.3% | 17.7% | 8.3% | 20.4% | 18.8% | 16.1% | 30.7% | 19.6% | 24.6% | 17.5% |
| Payouts / FCF | 6.6% | 2.3% | 63.6% | β | 155.6% | 0.0% | 0.0% | 0.0% | 0.0% | 30.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 7.0 | 5.0 | 5.0 | 7.0 | 4.0 | 6.0 | 3.0 | 5.0 |
| Altman Z'' | β1.0 | 0.4 | 5.2 | 10.5 | 4.2 | 5.6 | 7.2 | 12.6 | 11.5 | 6.8 |
| Accruals ratio | β11.3% | β12.0% | β5.3% | 47.8% | β4.0% | β1.6% | β16.6% | 0.3% | β11.7% | 6.0% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0000886163). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
